Briva50 ml

Briva is a synaptic vesicle protein 2A (SV2A) ligand antiepileptic drug (AED). Its established and evidence-based uses are:

• Partial-onset (focal) seizures — FDA-approved/established use: Briva is indicated as adjunctive (add-on) therapy or as monotherapy for the treatment of partial-onset seizures in adults and pediatric patients 1 month of age and older with epilepsy.
• Adjunct combination therapy: Most commonly, Briva is added to an existing antiepileptic regimen when seizures are not adequately controlled on other agents.
• Off-label use (not FDA-approved, limited evidence): Briva has been used off-label for status epilepticus (as an intravenous option) and in other seizure types in some clinical settings; such use should be guided by a specialist physician.

Each Brivaracetam tablet/oral solution/intravenous injection contains Brivaracetam as the active ingredient. It is available in multiple strengths (commonly 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg tablets; 10 mg/mL oral solution; and 10 mg/mL solution for intravenous injection). Tablets also contain standard excipients such as lactose, microcrystalline cellulose, and film-coating agents; formulations may vary by manufacturer.

Briva is a third-generation antiepileptic drug chemically related to levetiracetam. It works by selectively binding to synaptic vesicle protein 2A (SV2A) in the brain, which is thought to modulate neurotransmitter release and reduce abnormal neuronal excitability that leads to seizures. Briva is used in the long-term management of partial-onset (focal) seizures, either alone or together with other antiepileptic medicines, and is available as oral tablets, oral solution, and an intravenous formulation for use when oral administration is not feasible.

Briva belongs to the class of antiepileptic drugs (AEDs), specifically the synaptic vesicle protein 2A (SV2A) ligand class, structurally related to levetiracetam (racetam derivatives).

Brivaracetam exhibits high and selective binding affinity for synaptic vesicle protein 2A (SV2A), a transmembrane glycoprotein present in synaptic vesicles that is believed to participate in vesicle fusion and neurotransmitter release. By binding SV2A, Brivaracetam is thought to modulate synaptic neurotransmitter release and dampen the abnormal, hypersynchronous neuronal firing that underlies seizure activity. Its exact mechanism in the treatment of epilepsy has not been fully established.

Pharmacokinetics: Brivaracetam is rapidly and almost completely absorbed after oral administration (bioavailability ~100%), with peak plasma concentration reached within about 1 hour. It is extensively metabolized in the liver (mainly via hydrolysis and, to a lesser extent, CYP2C19-mediated hydroxylation), with an elimination half-life of approximately 9 hours. It is primarily excreted in the urine as metabolites.

Briva tablets and oral solution can be taken with or without food, twice daily. The oral solution should be measured with an appropriate calibrated measuring device. The intravenous form of Briva is administered by a healthcare professional as a slow injection or infusion over 2–15 minutes.

Briva has relatively few clinically significant drug interactions compared with older antiepileptic drugs, but the following are well-documented:

• Rifampin: Rifampin significantly decreases Briva plasma concentrations by inducing its metabolism; a dose increase of Briva may be needed during concomitant use.
• Carbamazepine: Briva can increase the active metabolite of carbamazepine, potentially increasing carbamazepine-related adverse effects (e.g., dizziness, diplopia); dose reduction of carbamazepine may be needed.
• Phenytoin: Briva can increase phenytoin plasma concentrations, requiring monitoring and possible phenytoin dose adjustment.
• Levetiracetam: Concomitant use with levetiracetam is not expected to provide additional therapeutic benefit, as both drugs act on the same target (SV2A).
• CNS depressants (opioids, benzodiazepines, sedatives) and alcohol: Concomitant use with Briva may increase somnolence and CNS-depressant effects.

Common side effects of Briva (occurring in clinical trials at meaningfully higher rates than placebo) include:

• Somnolence and sedation
• Dizziness
• Fatigue
• Nausea and vomiting
• Upper respiratory tract infection

Serious but less common effects requiring prompt medical attention:

• Psychiatric symptoms: irritability, aggression, agitation, anxiety, depression, psychotic symptoms, and rare suicidal ideation or behavior — patients and caregivers should watch for mood or behavior changes and seek medical advice promptly if these occur.
• Hypersensitivity reactions: rash, hives, swelling of the face/lips/tongue, or difficulty breathing — seek emergency care if these occur (see Contraindications).
• Impaired coordination and gait disturbance due to CNS-depressant effects.

Pregnancy: Data on the use of Briva in pregnant women are limited. As with other antiepileptic drugs, uncontrolled seizures during pregnancy pose risks to both mother and fetus, so Briva should be used during pregnancy only if the potential benefit of seizure control justifies the potential risk to the fetus, and only under close physician supervision. Discontinuation should not be done without medical advice, as abrupt withdrawal can precipitate seizures. Enrollment in an antiepileptic drug pregnancy registry, where available, is encouraged to help monitor outcomes.

Lactation: Briva passes into breast milk. A decision should be made whether to discontinue breastfeeding or discontinue the medicine, taking into account the benefit of breastfeeding and the mother's clinical need for Briva; consult a physician before breastfeeding while using this medicine.

Psychiatric effects: Briva may cause or worsen irritability, aggression, depression, and, rarely, suicidal thoughts or behavior. Patients and caregivers should be counseled to report any new or worsening mood or behavioral changes promptly (see Side Effects).

CNS depression: Briva commonly causes somnolence and fatigue, especially at treatment initiation; patients should avoid driving or operating machinery until they know how the medicine affects them, and should use caution with alcohol or other CNS-depressant medicines.

Do not discontinue abruptly: Stopping Briva suddenly can increase seizure frequency or precipitate status epilepticus; the dose should be tapered gradually under medical supervision unless a serious adverse reaction requires rapid discontinuation.

Hepatic and renal impairment: Dose adjustment of Briva is recommended in patients with hepatic impairment (see Use in Special Populations); caution is advised in severe renal impairment.

Use exactly as prescribed; do not change the dose or stop Briva without consulting your physician.

Reported symptoms of Briva overdose include somnolence and sedation. There is no specific antidote for Briva overdose. In case of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and may include general symptomatic and supportive measures; Briva can be removed by hemodialysis if clinically necessary.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze the oral solution. Discard any unused oral solution after the period specified on the label (commonly around 5 months after first opening, per the manufacturer's instructions).

Hepatic impairment: Dose reduction of Briva is recommended in patients with mild, moderate, or severe hepatic impairment; the maximum recommended dose is lower than in patients with normal hepatic function. Consult a physician for individualized dosing.

Renal impairment: No dose adjustment is generally required in mild-to-severe renal impairment; Briva is not recommended in patients with end-stage renal disease undergoing dialysis due to limited data, and the drug is removed by hemodialysis.

Elderly: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients, but caution is advised given the greater frequency of hepatic, renal, or cardiac impairment and concomitant medication use in this age group.

Pediatric use: see Pediatric Uses.

Briva is generally used as a long-term, chronic maintenance therapy for epilepsy, and duration of treatment should be determined by the treating physician based on seizure control, tolerability, and overall clinical course. It is not intended for short-term or as-needed use, and should not be discontinued without medical supervision (see Precautions and Warnings).

Antiepileptic drug (AED); synaptic vesicle protein 2A (SV2A) ligand.

Brivaracetam selectively binds to synaptic vesicle protein 2A (SV2A) in the brain, modulating neurotransmitter release from nerve terminals and thereby reducing the abnormal, excessive neuronal firing associated with seizures. The precise mechanism by which SV2A binding translates into an antiepileptic effect has not been fully elucidated.

Briva is approved for the treatment of partial-onset seizures (as adjunctive therapy or monotherapy) in children 1 month of age and older, with weight-based dosing (see Dosage and Administration). Safety and effectiveness of Briva in children younger than 1 month of age have not been established. As in adults, pediatric patients and caregivers should be monitored for psychiatric/behavioral changes and somnolence, and the medicine should not be stopped abruptly.